S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
S&P 500   5,130.95
DOW   38,989.83
QQQ   444.02
5 Under-the-Radar Artificial Intelligence (AI) Stocks
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Monday, 3/4/2024
Macy's, United Rentals rise; Apple, Spirit Airlines fall Monday, 3/4/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
DeSantis names Disney World district administrator to run elections in Democratic Orange County
Stock market today: Asian shares are mixed as China unveils 5% economic growth target for 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Ohio foundation begins process to distribute millions in opioid settlement money
Closing prices for crude oil, gold and other commodities
NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

$2.05
+0.01 (+0.49%)
(As of 03/4/2024 ET)
Today's Range
$1.99
$2.09
50-Day Range
$1.04
$2.20
52-Week Range
$1.61
$10.24
Volume
81,855 shs
Average Volume
131,984 shs
Market Capitalization
$208.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

Mesoblast MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
595.1% Upside
$14.25 Price Target
Short Interest
Healthy
0.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Mesoblast in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

514th out of 960 stocks

Biological Products, Except Diagnostic Industry

83rd out of 157 stocks


MESO stock logo

About Mesoblast Stock (NASDAQ:MESO)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Stock Price History

MESO Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Mesoblast Financial Results and Corporate Update Webcast
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MESO Jul 2024 2.500 call
Top 10 at 10: FDA wins on a Friday
Why are Mesoblast shares rocketing 28% today?
Mesoblast Limited (LWB.F)
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/30/2023
Today
3/04/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$34.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+595.1%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-81,890,000.00
Net Margins
-1,061.43%
Pretax Margin
-1,094.53%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$6.16 per share

Miscellaneous

Free Float
82,446,000
Market Cap
$208.14 million
Optionable
Optionable
Beta
3.44
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 67)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
    Comp: $737.81k
  • Dr. Eric A. Rose M.D. (Age 73)
    Chief Medical Officer & Executive Director
    Comp: $624.68k
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc. (Age 56)
    L.L.B., LLB (Hons), General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster BSc (Age 47)
    M.B.A., MS, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., MMS, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing
  • Ms. Niva Sivakumar B.Com.
    L.L.B., Joint Company Secretary
  • Mr. Paul Hughes BPHARM
    Joint Company Secretary














MESO Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price target for 2024?

6 brokerages have issued 1 year price targets for Mesoblast's shares. Their MESO share price targets range from $3.00 to $34.00. On average, they anticipate the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 595.1% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2024?

Mesoblast's stock was trading at $2.20 at the beginning of 2024. Since then, MESO shares have decreased by 6.8% and is now trading at $2.05.
View the best growth stocks for 2024 here
.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our MESO earnings forecast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) issued its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The company earned $2.14 million during the quarter, compared to the consensus estimate of $2 million. Mesoblast had a negative trailing twelve-month return on equity of 16.32% and a negative net margin of 1,061.43%.

When did Mesoblast's stock split?

Mesoblast shares reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of retail and institutional investors. Top institutional investors include Penbrook Management LLC (0.28%), Citadel Advisors LLC (0.00%), Affinity Asset Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MESO) was last updated on 3/5/2024 by MarketBeat.com Staff